These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

89 related articles for article (PubMed ID: 24273881)

  • 1. IL-35: a potential target for the treatment of atherosclerosis.
    Huang Y; Lin YZ; Shi Y; Ji QW
    Pharmazie; 2013 Oct; 68(10):793-5. PubMed ID: 24273881
    [TBL] [Abstract][Full Text] [Related]  

  • 2. IL-35, an anti-inflammatory cytokine which expands CD4+CD25+ Treg Cells.
    Castellani ML; Anogeianaki A; Felaco P; Toniato E; De Lutiis MA; Shaik B; Fulcheri M; Vecchiet J; Tetè S; Salini V; Theoharides TC; Caraffa A; Antinolfi P; Frydas I; Conti P; Cuccurullo C; Ciampoli C; Cerulli G; Kempuraj D
    J Biol Regul Homeost Agents; 2010; 24(2):131-5. PubMed ID: 20487626
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cytokine therapy with interleukin-2/anti-interleukin-2 monoclonal antibody complexes expands CD4+CD25+Foxp3+ regulatory T cells and attenuates development and progression of atherosclerosis.
    Dinh TN; Kyaw TS; Kanellakis P; To K; Tipping P; Toh BH; Bobik A; Agrotis A
    Circulation; 2012 Sep; 126(10):1256-66. PubMed ID: 22851544
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [The biological function and significance of IL-35 in the pathogenesis of atherosclerosis].
    Staciwa M; Broncel M
    Pol Merkur Lekarski; 2018 Apr; 44(262):161-164. PubMed ID: 29775441
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neutralization of IL-17 by active vaccination inhibits IL-23-dependent autoimmune myocarditis.
    Sonderegger I; Röhn TA; Kurrer MO; Iezzi G; Zou Y; Kastelein RA; Bachmann MF; Kopf M
    Eur J Immunol; 2006 Nov; 36(11):2849-56. PubMed ID: 17039570
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Airway inflammation and IgE production induced by dust mite allergen-specific memory/effector Th2 cell line can be effectively attenuated by IL-35.
    Huang CH; Loo EX; Kuo IC; Soh GH; Goh DL; Lee BW; Chua KY
    J Immunol; 2011 Jul; 187(1):462-71. PubMed ID: 21613618
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interleukin 12 induces T-cell recruitment into the atherosclerotic plaque.
    Zhang X; Niessner A; Nakajima T; Ma-Krupa W; Kopecky SL; Frye RL; Goronzy JJ; Weyand CM
    Circ Res; 2006 Mar; 98(4):524-31. PubMed ID: 16424368
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Progress on the relationship between IL-35 and respiratory allergic disease].
    Li J; Huang JJ
    Lin Chuang Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2017 Apr; 31(7):568-571. PubMed ID: 29871315
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Interleukin-23: A New Atherosclerosis Target.
    Liu W; Chang C; Hu H; Yang H
    J Interferon Cytokine Res; 2018 Oct; 38(10):440-444. PubMed ID: 30328797
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Epstein-Barr virus-induced gene 3 and the p35 subunit of interleukin 12 form a novel heterodimeric hematopoietin.
    Devergne O; Birkenbach M; Kieff E
    Proc Natl Acad Sci U S A; 1997 Oct; 94(22):12041-6. PubMed ID: 9342359
    [TBL] [Abstract][Full Text] [Related]  

  • 11. IFN-γ induced by IL-12 administration prevents diabetes by inhibiting pathogenic IL-17 production in NOD mice.
    Zhang J; Huang Z; Sun R; Tian Z; Wei H
    J Autoimmun; 2012 Feb; 38(1):20-8. PubMed ID: 22186068
    [TBL] [Abstract][Full Text] [Related]  

  • 12. IFN-beta inhibits human Th17 cell differentiation.
    Ramgolam VS; Sha Y; Jin J; Zhang X; Markovic-Plese S
    J Immunol; 2009 Oct; 183(8):5418-27. PubMed ID: 19783688
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The potential role of IL-37 in atherosclerosis.
    Wu BW; Zeng QT; Meng K; Ji QW
    Pharmazie; 2013 Nov; 68(11):857-60. PubMed ID: 24380232
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inflammatory cytokines provide a third signal for activation of naive CD4+ and CD8+ T cells.
    Curtsinger JM; Schmidt CS; Mondino A; Lins DC; Kedl RM; Jenkins MK; Mescher MF
    J Immunol; 1999 Mar; 162(6):3256-62. PubMed ID: 10092777
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Divergent pro- and antiinflammatory roles for IL-23 and IL-12 in joint autoimmune inflammation.
    Murphy CA; Langrish CL; Chen Y; Blumenschein W; McClanahan T; Kastelein RA; Sedgwick JD; Cua DJ
    J Exp Med; 2003 Dec; 198(12):1951-7. PubMed ID: 14662908
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The regulatory, inflammatory, and T cell programming roles of interleukin-2 (IL-2).
    Lan RY; Selmi C; Gershwin ME
    J Autoimmun; 2008 Aug; 31(1):7-12. PubMed ID: 18442895
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inducible IL-12-producing B cells regulate Th2-mediated intestinal inflammation.
    Sugimoto K; Ogawa A; Shimomura Y; Nagahama K; Mizoguchi A; Bhan AK
    Gastroenterology; 2007 Jul; 133(1):124-36. PubMed ID: 17631137
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chemotactic cytokines and inflammation. Biological properties of the lymphocyte and monocyte chemotactic factors ELCF, MCAF and IL-8.
    Zachariae CO
    Acta Derm Venereol Suppl (Stockh); 1993; 181():1-37. PubMed ID: 7901957
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of interleukin-12 in the induction of mucosal inflammation and abrogation of regulatory T cell function in chronic experimental colitis.
    Liu Z; Geboes K; Heremans H; Overbergh L; Mathieu C; Rutgeerts P; Ceuppens JL
    Eur J Immunol; 2001 May; 31(5):1550-60. PubMed ID: 11465113
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Interleukin-12: clinical usage and molecular markers of cancer susceptibility.
    Yuzhalin AE; Kutikhin AG
    Growth Factors; 2012 Jun; 30(3):176-91. PubMed ID: 22515181
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.